The global Dry Eye Syndrome Treatment Market is gearing up for unprecedented growth, set to secure a commendable Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period. According to the latest market insights, the industry is currently valued at an impressive US$ 5,120 million in 2023 and is poised to soar to a staggering US$ 9,521 million by the year 2033.

This substantial expansion is attributed to the rising prevalence of dry eye syndrome worldwide, coupled with advancements in treatment modalities. As individuals across the globe become increasingly conscious of eye health, the demand for effective and innovative treatments for dry eye syndrome is witnessing a significant upswing.

Download The Fee Sample PDf of This Report
https://www.futuremarketinsights.com/reports/sample/rep-gb-1215

One such example is the Narayana Nethralaya, a super specialty eye hospital based out of India, a dedicated lab to diagnose and treat dry eyes. This lab aims to provide patients with awareness about eye lid problems such as Meibomian gland dysfunction, which lead to the development of dry eye syndrome.

Also, similar trend is observed in developed market such as U.S. Various government awareness campaigns and not for profit initiatives try to create awareness about the dry eye disease to the population that does not have access to eye care facilities. Eye Care America is an example of a public service organization run by the American Academy of Ophthalmology Foundation that provides free eye care through volunteer ophthalmologists.

Further, those who are age 65 or older and who have not seen an ophthalmologist in three or more years may be eligible to receive a comprehensive, medical eye exam and up to one year of care at no out-of-pocket cost. This consequently will increase the utilization of dry eye treatment products and drive the growth of the dry eye syndrome treatment market during the forecast period. .

Key Takeaways from Dry Eye Syndrome Treatment Study

  • Greater acceptance of artificial tears owing to improved patient comfort leads the artificial tears segment to account for the maximum share of 60.8% in 2021, expanding at 7.1% CAGR during the forecast period.
  • By prescription, Rx prescriptions are projected to account for 71.3% of the market share in 2022 indicating highest demand, since majority of population visit hospitals to get the checkup done, in turn increasing the numbers of Rx prescriptions.
  • Retail pharmacies, as distribution channel held the largest share of 60.8% in 2021 and is expected to grow with the same trend throughout the forecast period.
  • By region, North America held the largest share of 37.6% of the dry eye syndrome treatment market in 2021 indicating the growth due to high prevalence and high treatment adoption rate in North America.

Who is winning?

Key Players :

  • Allergen plc. (Abbvie)
  • Novartis AG
  • Otsuka Pharmaceuticals Co.Ltd.
  • Bausch Health Companies Inc.
  • Akron Inc.
  • Johnson & Johnson Inc.
  • Thea Pharmaceuticals Limited
  • OASIS Medical
  • Altaire Pharmaceuticals Inc.
  • Boiron USA
  • Similasan Corporation
  • Scope Ophthalmics Ltd.
  • Reckitt Benckiser Group PLC
  • Medicom Healthcare Ltd
  • FDC Limited.
  • Lupin Limited
  • Jamjoom Pharmaceuticals Co.
  • Sentiss Pharma Private limited.

Some of the leading manufacturers of dry-eye-syndrome treatment market focuses on the product launch and approvals with global expansion objectives, thereby, enhancing their market presence.

  • In January 2021, SIFI an Italy based international ophthalmic company launched SYNFO for moisturizing and lubrication in dry eye treatment.
  • In December 2020, Alcon Canada announced the launch of its new product Systane an ultra-hydration lubricant eye drops preservative free containing Hyaluronic acid and HP-guar
  • In November 2020, Santen Pharmaceutical launched Cationorm categorized as artificial tear for moisturisation and long lasting relief to dry eye.